相似文献
1
Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function.
Blood Adv. 2020 Apr 14;4(7):1321-1324. doi: 10.1182/bloodadvances.2020001553.
2
Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
J Oncol Pharm Pract. 2019 Jun;25(4):1021-1025. doi: 10.1177/1078155218815305. Epub 2018 Nov 26.
3
Daratumumab added to standard of care in patients with newly diagnosed multiple myeloma: A network meta-analysis.
Eur J Haematol. 2019 Dec;103(6):542-551. doi: 10.1111/ejh.13317. Epub 2019 Oct 1.
4
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12.
5
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.
Clin Chem Lab Med. 2016 Jun 1;54(6):1095-104. doi: 10.1515/cclm-2015-1031.
6
[Daratumumab for multiple myeloma].
Bull Cancer. 2018 Nov;105(11):985-991. doi: 10.1016/j.bulcan.2018.09.003. Epub 2018 Oct 24.
7
Daratumumab for the treatment of multiple myeloma.
Expert Opin Biol Ther. 2017 Jul;17(7):887-893. doi: 10.1080/14712598.2017.1322578. Epub 2017 May 2.
8
Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.
Blood. 2017 Aug 17;130(7):900-902. doi: 10.1182/blood-2017-01-763599. Epub 2017 Jun 14.
9
Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients.
Int J Hematol. 2019 Nov;110(5):559-565. doi: 10.1007/s12185-019-02715-w. Epub 2019 Aug 7.
10
EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
Oncologist. 2018 May;23(5):594-602. doi: 10.1634/theoncologist.2017-0328. Epub 2018 Jan 25.
引用本文的文献
1
Daratumumab treatment for kidney-involved light chain deposition disease prevents renal function progression: a case report with 3 years of follow-up and review of the literature.
Front Oncol. 2025 Jan 30;15:1466323. doi: 10.3389/fonc.2025.1466323. eCollection 2025.
2
Recent Updates in the Diagnosis and Management of Kidney Diseases in Multiple Myeloma.
Indian J Nephrol. 2025 Jan-Feb;35(1):8-20. doi: 10.25259/ijn_491_23. Epub 2024 Jul 24.
3
Daratumumab improves the hematological response and kidney function of patients with light chain deposition disease.
Chin Med J (Engl). 2025 Jan 20;138(2):246-248. doi: 10.1097/CM9.0000000000003374. Epub 2024 Nov 13.
4
Recurrent Fibrillary Glomerulonephritis Secondary to Chronic Lymphocytic Leukemia: Remission of Kidney Disease with Ibrutinib.
Case Rep Nephrol Dial. 2024 Oct 15;14(1):164-170. doi: 10.1159/000539742. eCollection 2024 Jan-Dec.
5
Light chain deposition disease: pathogenesis, clinical characteristics and treatment strategies.
Ann Hematol. 2025 Apr;104(4):2083-2093. doi: 10.1007/s00277-024-05911-9. Epub 2024 Aug 28.
6
Diagnosis of light‑chain deposition disease after renal transplantation: A case report and literature review.
Exp Ther Med. 2024 Jun 28;28(3):339. doi: 10.3892/etm.2024.12628. eCollection 2024 Sep.
7
Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Haematologica. 2024 Aug 1;109(8):2619-2627. doi: 10.3324/haematol.2023.284520.
8
Light chain deposition disease presenting with gastrointestinal disorder as primary manifestation: report of two cases and literature review.
J Int Med Res. 2024 Mar;52(3):3000605241233972. doi: 10.1177/03000605241233972.
9
Successful Treatment with Daratumumab of a Patient with Monoclonal Lambda Light Chain Disease Presenting as Nephrotic Syndrome and Crescentic Glomerulonephritis.
Acta Haematol. 2024;147(5):598-603. doi: 10.1159/000536283. Epub 2024 Jan 16.
10
Dyspnea and cough in a 68-year-old female with light chain deposition disease.
Respir Med Case Rep. 2023 Mar 20;43:101839. doi: 10.1016/j.rmcr.2023.101839. eCollection 2023.
本文引用的文献
1
Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis.
Leukemia. 2019 Feb;33(2):531-536. doi: 10.1038/s41375-018-0262-2. Epub 2018 Sep 28.
2
Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications.
Blood. 2018 Oct 4;132(14):1478-1485. doi: 10.1182/blood-2018-04-839480. Epub 2018 Jul 16.
3
Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.
Leukemia. 2018 Mar;32(3):729-735. doi: 10.1038/leu.2017.286. Epub 2017 Sep 18.
4
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Blood. 2017 Aug 24;130(8):974-981. doi: 10.1182/blood-2017-05-785246. Epub 2017 Jun 21.
5
Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.
Blood. 2017 Aug 17;130(7):900-902. doi: 10.1182/blood-2017-01-763599. Epub 2017 Jun 14.
6
AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis.
Blood. 2017 Aug 3;130(5):632-642. doi: 10.1182/blood-2017-02-767475. Epub 2017 May 26.
7
Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome.
Blood. 2017 Aug 3;130(5):625-631. doi: 10.1182/blood-2017-02-767467. Epub 2017 May 25.
8
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751.
9
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038.
10
First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis.
Blood. 2016 Oct 13;128(15):1987-1989. doi: 10.1182/blood-2016-06-722496. Epub 2016 Aug 19.
Zotero 插件